Division of Gastroenterology, Department of Medicine, NYU School of Medicine, New York, NY, USA.
Department of Microbiology, NYU School of Medicine, New York, NY, USA.
Aliment Pharmacol Ther. 2020 Jun;51(12):1222-1232. doi: 10.1111/apt.15770. Epub 2020 May 5.
The initiating events of chronic gastrointestinal (GI) inflammation in Crohn's disease (CD) and ulcerative colitis (UC) are not well-defined, but GI infections are implicated.
To define the role of GI infections in risk of incident inflammatory bowel disease (IBD) and synthesise the current body of relevant translational data to provide biological context for associations between GI infections and IBD risk.
We systematically reviewed electronic databases through February 2020. Clinical studies that provided risk estimates of the association between GI infections and incident IBD were included. Inclusion criteria were broader for translational studies aiming to define mechanisms of GI infections and predisposition to or protection from IBD.
Of the studies identified, 63 met full inclusion criteria. Among studies of clinical gastroenteritis, bacteria-specifically, Salmonella species, Campylobacter species and Clostridioides difficile-demonstrated consistent positive associations with risk of incident IBD. Of viruses, norovirus was associated with increased risk of incident CD. Regarding inverse associations with incident IBD, Helicobacter pylori and helminth infections were associated with a generally consistent reduced risk of IBD. Based on a qualitative analysis of the translational data, putative mechanisms involve multiple microbial and immunologic pathways.
Based on this systematic review, certain enteric pathogens are associated with an increased risk of incident IBD, while others are potentially protective. Prospective studies are required to clarify the clinical implications of these enteric pathogens on the risk and course of IBD, and possible therapeutic or preventative benefit.
克罗恩病(CD)和溃疡性结肠炎(UC)慢性胃肠道(GI)炎症的起始事件尚不清楚,但胃肠道感染与此有关。
确定胃肠道感染在炎症性肠病(IBD)发病风险中的作用,并综合当前相关转化研究的数据,为胃肠道感染与 IBD 风险之间的关联提供生物学背景。
我们系统地检索了截至 2020 年 2 月的电子数据库。纳入了提供胃肠道感染与新发 IBD 关联风险估计的临床研究。对于旨在确定胃肠道感染机制以及对 IBD 的易感性或保护作用的转化研究,纳入标准更为宽泛。
在确定的研究中,有 63 项符合全部纳入标准。在临床胃肠炎研究中,具体来说,沙门氏菌属、弯曲菌属和艰难梭菌与新发 IBD 的风险呈一致的正相关。在病毒中,诺如病毒与新发 CD 的风险增加相关。关于与新发 IBD 的负相关,幽门螺杆菌和寄生虫感染与 IBD 风险降低有关。基于转化数据的定性分析,推测的机制涉及多种微生物和免疫途径。
基于这项系统评价,某些肠道病原体与新发 IBD 的风险增加有关,而其他病原体则可能具有保护作用。需要前瞻性研究来阐明这些肠道病原体对 IBD 风险和病程的临床意义,以及可能的治疗或预防益处。